Smith+Nephew signs exclusive distribution agreement to bring unique NAVBIT SPRINT™ solution for accurate acetabular cup alignment to Japan
From left: Dr. Matt Lyons (Orthopedic Surgeon, Australia), Mr. Shinya Dobashi (SVP & MD, S+N North Asia), Ms. Ameneh Sadeghpour (Chief Strategy & BD Officer, Navbit), Mr. Damien Ben-L’Amri (Sr. Director, Orthopedics, S+N Asia Pacific), Mr. Taku Mizuno (Sr. Director, Orthopedics, S+N Japan)
Small, disposable, compact and simple to use navigation tool offers surgeons speed and reliability without the financial burden of capital equipment
LONDON, April 11, 2023 /PRNewswire/ — Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces an agreement with NAVBIT to exclusively distribute the NAVBIT SPRINT disposable navigation device for use in primary hip arthroplasty in Japan. NAVBIT SPRINT delivers a fast and reliable alternative to capital investment improving efficiencies for hospitals.
Post-operative dislocation is the number two most common reason for revision of a total hip replacement around the world1,2,3,4 and remains a serious concern for surgeons when performing total hip arthroplasty. Studies have shown reduced risk of dislocation when using navigation.5
The NAVBIT SPRINT device has been shown to be accurate to within an average error of 2.13° in cup inclination and 2.36° in cup anteversion.6
“Smith+Nephew’s new agreement with NAVBIT offers Japanese surgeons an exciting technology to improve outcomes and efficiencies in the operating room,” said Shinya Dobashi, Senior Vice President and Managing Director, North Asia, Smith+Nephew. “Only 49% of acetabular cups are accurately aligned when using manual instrumentation.7 NAVBIT SPRINT offers our customers a simple and accurate solution to achieve reproducible results.”
“In the past surgery was more art than science. Today we have higher expectations around the accuracy and precision of our surgery,” said Professor Bill Walter, Orthopaedic Surgeon and Founder of NAVBIT. “Outliers are becoming less acceptable to surgeons and to patients. Surgeons will have to answer the question: If there is a technology available that can make you more accurate, why are you not using it?”
“Japanese surgeons are the most sophisticated in their field. They are the leaders in understanding the complexities of hip surgery in 3 dimensions and the impact of movements of the spine and pelvis on the outcomes of hip replacement,” said Lynette Walter, CEO of NAVBIT. “Navbit is delighted to be working with the most capable, tech savvy surgeons in the world.”
NAVBIT’s SPRINT System is available through Smith+Nephew in Japan for either supine and lateral approaches to primary hip arthroplasty.
References
- Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2020 Annual Report, Adelaide; AOA, 2020: 1-474. [Available at: https://aoanjrr.sahmri.com/annual-reports-2020]
- National Joint Registry for England, Wales and Northern Ireland, 17th Annual Report. [Available at: http://www.njrcentre.org.uk/njrcentre]
- American Joint Replacement Registry (AJRR), The Seventh Annual Report of the AJRR on Hip and Knee Arthroplasty 2020, American Academy of Orthopaedic Surgeons
- Italian Arthroplasty Register, Addendum to the Annual Report 2019, English Version of Tables and Figures, October 2020
- Agarwal S, Eckhard L, Walter WL, et al. The Use of Computer Navigation in Total Hip Arthroplasty Is Associated with a Reduced Rate of Revision for Dislocation: A Study of 6,912 Navigated THA Procedures from the Australian Orthopaedic Association National Joint Replacement Registry. J Bone Joint Surg Am. 2021.
- Walter WL, Baker NA, Marsden-Jones D, Sageghpour A. Novel measure of acetabular cup inclination and anteversion during Total Hip Arthroplasty. 2022 in press.
- The John Charnley Award: Risk Factors for Cup Malpositioning: Quality Improvement Through a Joint Registry at a Tertiary Hospital. Malchau et al Clin Orthop Relat Res. 2011 Feb; 469(2): 319–329.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 19,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2022. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of Covid, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of Covid; economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers (including, without limitation, as a result of Covid); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of Covid); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.
™ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
Photo – https://mma.prnewswire.com/media/2049807/Smith_Newphew_NAVBIT.jpg
Logo – https://mma.prnewswire.com/media/3924/Smith_Nephew_Logo.jpg
SOURCE Smith & Nephew plc
